Please login to the form below

Not currently logged in
Email:
Password:

omecamtiv

This page shows the latest omecamtiv news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Jardiance for heart failure review

FDA fast-tracks Jardiance for heart failure review

year. Other contenders looking to meet the needs of heart failure patients include Amgen and Servier, whose omecamtiv mecarbil, recently passed a futility review in its phase 3 study.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    100. ‡‡Servier / Amgen .  Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... rights in Europe for omecamtiv mecarbil. †

  • Pharma deals during July 2013 Pharma deals during July 2013

    the US, and Servier receives an option to omecamtiv mecarbil for Europe. ... Omecamtiv mecarbil is currently in phase II trials for acute and chronic heart failure and is the most advanced drug candidate coming out of Amgen's collaboration with

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    129. Cytokinetics / Amgen. Extension of existing licence to Japan. Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics